Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.

Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.

Item
http://www.wikidata.org/entity/Q34057942
Recent developments in clinical trial designs for HIV vaccine researchCD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review.Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trialConserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects.FCGR2C Polymorphisms Associated with HIV-1 Vaccine Protection Are Linked to Altered Gene Expression of Fc-γ Receptors in Human B CellsPeptide Targeted by Human Antibodies Associated with HIV Vaccine-Associated Protection Assumes a Dynamic α-Helical Structure.Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models.HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition.Dynamics and Correlates of CD8 T-Cell Counts in Africans with Primary Human Immunodeficiency Virus Type 1 Infection.The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.Complex immune correlates of protection in HIV-1 vaccine efficacy trials.Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.Sanger and Next-Generation Sequencing data for characterization of CTL epitopes in archived HIV-1 proviral DNA.Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.Advances in HIV-1 Vaccine Development.
P2860

Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.

Item
http://www.wikidata.org/entity/Q34057942
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.
@ast
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.
@en
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.
@nl
type
label
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.
@ast
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.
@en
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.
@nl
prefLabel
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.
@ast
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.
@en
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932